可测量残留病作为急性髓系白血病强化治疗早期疗效终点的多国PETHEMA研究
该多国PETHEMA研究纳入2623例适合强化治疗且一疗程后达完全缓解的新诊断AML患者,评估流式细胞术检测MRD是否比形态学CR更敏感、最佳MRD cutoff及MRD阴性CR与OS的个体水平关联。68%患者检出MRD,MRD≥0.01-<0.1%与较差OS相关;0.01% cutoff的MRD阴性CR具独立预后价值并与OS个体水平显著相关(Global odds ratio 1.23;95%CI 1.02-1.40),但在特定遗传风险及巩固后治疗亚组中显著性丢失。
要点
- 流式MRD在68%的AML患者中可检出,MRD≥0.01-<0.1%与较差OS相关。
- 0.01% cutoff的MRD阴性CR具独立预后价值,与OS个体水平相关(Global OR 1.23;95%CI 1.02-1.40)。
- 特定遗传风险亚组及巩固后治疗亚组中MRD阴性CR与OS的关联显著性丢失。
核心结论
- 结果支持在特定AML亚组中开展正式研究,以探讨MRD作为早期疗效终点的作用。
研究设计与样本
- 多国PETHEMA真实世界研究,纳入2623例适合强化治疗且一疗程后达完全缓解的新诊断AML患者。
- 采用流式细胞术评估MRD,比较其与形态学CR的敏感性,并分析最佳cutoff及MRD阴性CR与OS的关联。
主要发现
- 68%的患者检出MRD,MRD水平≥0.01-<0.1%与较差OS相关。
- 0.01% cutoff的MRD阴性CR显示独立预后价值,并与OS在个体患者水平显著相关(Global odds ratio 1.23;95%CI 1.02-1.40)。
- 在特定遗传风险亚组及巩固后治疗亚组中,MRD阴性CR与OS的关联显著性丢失。
- 不同诱导方案下MRD阴性CR率与OS的关系总体可见。
关键数值与推荐
- MRD检出率68%。
- MRD水平≥0.01-<0.1%与较差OS相关。
- MRD阴性CR采用0.01% cutoff,Global odds ratio 1.23(95%CI 1.02-1.40)。
临床怎么用
- 对强化治疗的AML患者,可考虑用流式MRD(0.01% cutoff)辅助评估早期疗效和预后。
- 在特定遗传风险及巩固后治疗亚组中,MRD阴性CR的预后价值可能有限,需结合其他因素解读。
局限性
- MRD阴性CR与OS的关联在特定遗传风险亚组及巩固后治疗亚组中显著性丢失。
- 原文未报告具体遗传风险亚组、巩固后治疗类型及样本量等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Measurable residual disease (MRD) is an early endpoint of treatment efficacy in some hematological malignancies, but several questions remain unanswered to endorse its use in acute myeloid leukemia (AML). We leveraged PETHEMA real-world outcomes of 2623 newly-diagnosed AML patients fit for intensive therapy and in complete remission (CR) after one cycle, to investigate if MRD assessment using flow cytometry is more sensitive than morphological CR, what is the optimal MRD cutoff, the individual-patient-level association between MRD negative CR and overall survival (OS), and if MRD negative rates after different induction regimens associate with different OS. MRD was detected in 68% of patients and presence of MRD levels ≥0.01-<0.1% associated with inferior OS. MRD negative CR using the 0.01% cutoff showed independent prognostic value and was significantly correlated with OS at the individual patient-level (Global odds ratio 1.23; 95% CI, 1.02-1.40). However, significance was lost in specific subgroups defined by genetic risk and post-consolidation treatment. The relationship between treatment effect in MRD negative CR rates and OS after different induction regimens was generally observed. Altogether, these results support formal studies to investigate the role of MRD as an early endpoint of treatment efficacy in specific subgroups of AML patients.
引用
- Paiva B, Burgos L, Gonzalez C, et al. Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy. Leukemia. 2026. PMID: 42850349. doi:10.1038/s41375-026-03153-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。